Dr Awan on the Evolving Role of Bispecific Antibodies Treatment in DLBCL

Farrukh Awan, MD, professor, Department of Internal Medicine, UT Southwestern Medical Center, member, Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, discusses the evolving role of bispecific antibodies in the treatment paradigm of relapsed diffuse large B-cell lymphoma (DLBCL).
Despite the success of frontline therapy in curing a substantial proportion of patients with DLBCL, a significant subset of these patients will experience relapse, Awan begins. Historically, treatment options for relapsed disease were limited to salvage chemotherapy, immunotherapy, or CAR T-cell therapy. However, CAR T-cell therapy poses its own unique challenges. For example, the lengthy time that is often needed for manufacturing, which causes a higher risk of disease progression during this period, makes this treatment option inaccessible for individuals in need of immediate intervention, Awan explains.